BELLEVUE GROUP AG
Q1 2026 Form 13-F

KUESNACHT
CIK 0001674546 · Institutional investment manager
Consolidated report · includes 2 managers since Q1 2020
$4.2B Reported Value Total
Reported value
$4.2B
Quarter over quarter
-5.4%
Holdings
155
Top-10 concentration
42.0%

Filing Structure

Reports holdings for

  • Bellevue Asset Management UK Ltd · File #028-20408 · Q1 2024 – Q4 2025
  • BB Biotech AG (not a 13F filer in our records) · File #28-06964 · Q2 2019 – Q3 2024 · declared by one filing
  • Bellevue Asset Management AG (not a 13F filer in our records) · File #28-16892 · Q1 2016 – Q3 2024 · declared by one filing
  • Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · File #28-20408 · Q4 2020 – Q3 2024 · declared by one filing
  • Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · Q3 2020 – Q3 2020 · declared by one filing
  • Biotech Growth N V (not a 13F filer in our records) · File #028-11194 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Target N V (not a 13F filer in our records) · File #28-11189 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Invest N V (not a 13F filer in our records) · File #28-11191 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Focus N V (not a 13F filer in our records) · File #28-11193 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Growth N V (not a 13F filer in our records) · File #28-11194 · Q2 2019 – Q2 2019 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Christoph Eisenring / Stefano Montalbano
Head Legal & Compliance / CFO
Q4 2025
Q2 2026
Go to latest
Loading 13F Metrics

Q1 2026 13F filing summary

Period of report March 31, 2026
Filed May 15, 2026
Form 13F-HR
Reported value $4.2B
Positions 155
Change in reported value -20.4%
New positions 19
Exited positions 40
Position turnover 30.3%
Top-10 concentration 42.0%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
 148 $4.8B
Q1 2026 13F
Filed May 15, 2026
 155 $4.2B
Q4 2025 13F
Filed Feb 17, 2026
 176 $5.3B
Q3 2025 13F
Filed Nov 14, 2025
 148 $4.8B
Q2 2025 13F
Filed Aug 14, 2025
 142 $4.5B
Q1 2025 13F
Filed May 14, 2025
 148 $4.5B
Q4 2024 13F
Filed Feb 14, 2025
 160 $5.2B
Q3 2024 13F
Filed Nov 14, 2024
 162 $6.2B
Q2 2024 13F
Filed Aug 14, 2024
 166 $6.2B
Q1 2024 13F
Filed May 15, 2024
 169 $6.6B
Q4 2023 13F
Filed Feb 14, 2024
 161 $6.5B
Q3 2023 13F
Filed Nov 14, 2023
 154 $6.2B
Q2 2023 13F
Filed Aug 14, 2023
 156 $7.0B
Q1 2023 13F
Filed May 15, 2023
 159 $6.9B
Q4 2022 13F
Filed Feb 14, 2023
 171 $7.5B
Q3 2022 13F
Filed Nov 14, 2022
 176 $7.0B
Q2 2022 13F
Filed Aug 11, 2022
 172 $7.1B
Q1 2022 13F
Filed May 13, 2022
 177 $8.6B
Q4 2021 13F
Filed Feb 10, 2022
 191 $9.7B
Q3 2021 13F
Filed Nov 12, 2021
 219 $9.9B

22 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2026

# Holding Reported value % of portfolio
1 VRTX VERTEX PHARMACEUTICALS INC $304.5M 7.25%
2 ARGX ARGENX SE $228.6M 5.44%
3 REGN REGENERON PHARMACEUTICALS $215.3M 5.12%
4 SRRK SCHOLAR ROCK HLDG CORP $176.2M 4.19%
5 GILD GILEAD SCIENCES INC $163.0M 3.88%
6 RVMD REVOLUTION MEDICINES INC $150.2M 3.57%
7 IONS IONIS PHARMACEUTICALS INC $136.6M 3.25%
8 ISRG INTUITIVE SURGICAL INC $132.1M 3.14%
9 VRDN VIRIDIAN THERAPEUTICS INC $131.6M 3.13%
10 KRYS KRYSTAL BIOTECH INC $124.5M 2.96%
11 CRNX CRINETICS PHARMACEUTICALS IN $119.1M 2.84%
12 ABT ABBOTT LABORATORIES $118.2M 2.81%
13 NUVL NUVALENT INC $107.9M 2.57%
14 AMGN AMGEN INC $103.9M 2.47%
15 BSX BOSTON SCIENTIFIC CORP $92.0M 2.19%
16 ELVN ENLIVEN THERAPEUTICS INC $91.0M 2.17%
17 IMCR IMMUNOCORE HLDGS PLC $84.3M 2.01%
18 MDT MEDTRONIC PLC $83.0M 1.97%
19 ALNY ALNYLAM PHARMACEUTICALS INC $77.6M 1.85%
20 RLAY RELAY THERAPEUTICS INC $77.6M 1.85%

Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings